hC Bioscience
- Company typePrivate
- Founded2021
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
hC Bioscience firmographics
Firmographics- Name
- hC Bioscience
- Legal name
- hC Bioscience
- Website
- https://hcbioscience.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Closed
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
hC Bioscience industry classification
Industry- Product category
- Biotechnology - Protein Editing Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE)
- akta.pro secondary industries
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
Keywords
Where hC Bioscience is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
hC Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Revenue model
- Therapeutic Development and Licensing: Pre-revenue biotech company developing tRNA-based therapeutics targeting genetic diseases and cancer. Revenue model would likely involve pharmaceutical licensing, co-development partnerships, and eventual product commercialization.
hC Bioscience product offering
Product offeringCore offering
hC Bioscience developed engineered transfer RNA (tRNA)-based therapeutics that perform targeted protein editing to treat genetically defined diseases and cancer. The company operated two proprietary platforms: PTCX, which enables read-through of premature termination codons (nonsense mutations) to produce full-length functional proteins, and SWTX, which corrects single amino acid errors caused by missense mutations. The company was pre-commercial and focused on discovery and preclinical development of tRNA-based protein editing therapies.
Product overview
hC Bioscience was a biotech company developing tRNA-based therapeutics (transfer RNA therapies) for genetically defined diseases, focusing on cancer and genetic disorders. The company operated two proprietary platforms: PTCX for addressing premature termination codons and SWTX for correcting missense mutations. These protein-editing therapies based on engineered tRNAs aimed to treat genetically defined diseases by enabling the production of full-length functional proteins or correcting amino acid errors. Note: The company shut down in 2025.
Differentiator
Problem solved
Functional benefit
Products and services
- PTCX Platform
- SWTX Platform
Companies that use hC Bioscience
Customer profileSegments1 record
Ideal customer profiles1 record
hC Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
hC Bioscience partnerships and signals
Strategic signalScale indicators3 records
Recent moves4 records
Expansion highlights2 records
hC Bioscience competitors and assessment
Company assessmentDirect peers
- Tevard Biosciences: Tevard is the closest direct peer — also developing engineered tRNA-based therapeutics (suppressor tRNAs) to read through premature termination codons in genetic diseases and nonsense mutation-driven disorders, including Dravet syndrome and Duchenne muscular dystrophy. It shares hC Bioscience's core scientific thesis on tRNA-mediated protein editing.
- ReCode Therapeutics: ReCode develops mRNA and tRNA-based therapeutics for genetic diseases including primary ciliary dyskinesia and cystic fibrosis, using lipid nanoparticle delivery. It overlaps with hC Bioscience in RNA-therapeutic modality and rare-disease focus.
- ProQR Therapeutics: ProQR develops RNA-based therapies (Axolotl platform using single-stranded RNA oligonucleotides) for genetic diseases including Usher syndrome and cystic fibrosis. It shares the 'edit the RNA, fix the protein' thesis and rare-disease focus with hC Bioscience.
Broad incumbents
- Beam Therapeutics: Beam is a clinical-stage base-editing company targeting similar genetic-disease mutation classes. It is a much larger, well-capitalized player competing for the same partnership and capital pool as hC Bioscience in the genetic-medicines space.
- Verve Therapeutics: Verve is a clinical-stage genetic medicines company developing in vivo gene editing for cardiovascular disease. While focused on a different therapeutic area, it competes for the same genetic-medicine capital and partnership attention as tRNA platforms.
- Editas Medicine: Editas is a clinical-stage CRISPR/gene-editing company developing therapies for genetic diseases. It is a broader incumbent competing in the same overall genetic-medicines category as hC Bioscience.
- Intellia Therapeutics: Intellia is a clinical-stage CRISPR genome-editing company targeting genetic diseases and oncology. As a well-capitalized incumbent in genetic medicines, it competes for partnership, talent, and capital relevant to tRNA-based approaches.
- Alnylam Pharmaceuticals: Alnylam is the leading siRNA therapeutics company, with multiple approved products and a broad rare-disease pipeline. It defines the competitive RNA-therapeutics commercial benchmark and shares target patient populations (rare genetic diseases) with hC Bioscience.
- Moderna: Moderna is the leading mRNA therapeutics and vaccines company, with platform capabilities in RNA design, LNP delivery, and manufacturing that are directly applicable to tRNA-based therapeutics. It is a broad incumbent defining capital and partnership dynamics across RNA medicines.
Emerging players
- Shape Therapeutics: Shape is a preclinical-stage RNA editing company using ADAR-based approaches to correct point mutations in genetic disease transcripts. It addresses the same missense/nonsense mutation space as hC Bioscience via a different RNA-modality mechanism.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
hC Bioscience social profiles
Digital presencehC Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
hC Bioscience leadership team
Management profileNumber of profiles
hC Bioscience funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
hC Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about hC Bioscience
What does hC Bioscience do?
hC Bioscience developed engineered transfer RNA (tRNA)-based therapeutics that perform targeted protein editing to treat genetically defined diseases and cancer. The company operated two proprietary platforms: PTCX, which enables read-through of premature termination codons (nonsense mutations) to produce full-length functional proteins, and SWTX, which corrects single amino acid errors caused by missense mutations. The company was pre-commercial and focused on discovery and preclinical development of tRNA-based protein editing therapies.
Is hC Bioscience a public or private company?
hC Bioscience is a private company. It is classified as venture growth investor backed and is currently closed.
When was hC Bioscience founded?
hC Bioscience was founded in 2021. It employs 1 to 10 people.
Where is hC Bioscience based?
hC Bioscience is headquartered in Cambridge, United States, in the North America region.
How does hC Bioscience make money?
One revenue line is on record: therapeutic Development and Licensing.
Who are hC Bioscience's main competitors?
Direct peers on record are Tevard Biosciences, ReCode Therapeutics and ProQR Therapeutics. Broad incumbents are Beam Therapeutics, Verve Therapeutics, Editas Medicine, Intellia Therapeutics, Alnylam Pharmaceuticals and Moderna. Shape Therapeutics is listed as an emerging player.
Does hC Bioscience have an API?
No public API is recorded for hC Bioscience.
What industry is hC Bioscience in?
hC Bioscience's product category is Biotechnology - Protein Editing Therapeutics. Its primary akta.pro industry code is HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2834.